The pharmacological blockade of CCK2 receptors may be an effective new therapeutic approach for blocking tumor-stellate cell communication and rewiring the TME through normalized human tumor vasculature and reduced stellate cell activation. The gene discussed is CCKBR; the disease is neoplasm.